FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

Synta earns $25M milestone from GSK pact

Synta Pharmaceuticals has earned a $25 million pay out from GlaxoSmithKline. And it stands to earn another two $25 million checks as Glaxo advances the cancer drug elesclomol, which is in a late-stage study as a treatment for skin cancer. The therapy triggers apoptosis, or programmed cell death.

When Lexington, MA-based Synta signed up on its development pact with Glaxo a year ago, it outlined a set of milestones worth up to $585 million and gained $80 million up front. The deal calls for $145 million in milestones for melanoma and $440 million for other cancer indications. Synta was a 2007 Fierce 15 company.

- check out Synta's release
- read the AP report

Related Articles:
Melanoma therapy produces positive mid-stage data
Synta outlines cash flow from Glaxo pact
Synta scores $1.1B deal with GSK

More stories about GlaxoSmithKline   milestones   Synta Pharmaceuticals  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 75 + 5?
To combat spam, please solve the math question above.